The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

DENVER — The use of several common antibiotics led to exacerbation of myasthenia gravis in a small cohort of patients, Sanem P. Uysal, MD, said in this Healio video from the American Academy of ...

The landscape of gMG treatment is rapidly evolving, said John Morren, MD, of the Cleveland Clinic. The traditional approach to managing gMG involves broad immunosuppressive therapies, but emerging ...

Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice ...

AstraZeneca has bagged a win for its rare disease pipeline, with its Phase III trial of gefurulimab demonstrating the drug’s ...

Spotlight On > gMG Myasthenia Gravis Exacerbations — Emerging treatments focus on more precise immune modulation. by Paul Smyth, MD, Contributing Writer, MedPage Today March 7, 2025 • 4 min read ...

“Myasthenia Gravis Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Myasthenia Gravis ...

Myasthenia gravis, or MG, is a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue. ... it's often treated by administering one of five FDA-approved medications.

Investigational nipocalimab reduced serum immunoglobulin G (IgG), improved functional scores, and was well tolerated in adolescents with generalized myasthenia gravis, according to data from an ...

Andrea Divis was diagnosed with myasthenia gravis in 2018. Here, ... I was sliced open across my neck, suddenly taking handfuls of medications, and dealing with the unknown.